Clinical Cancer Research Holland2
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 14, 5099-5107, August 15, 2008. doi: 10.1158/1078-0432.CCR-08-0255
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Lazzarini, R.
Right arrow Articles by Catalano, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lazzarini, R.
Right arrow Articles by Catalano, A.

Cancer Therapy: Preclinical

Enhanced Antitumor Therapy by Inhibition of p21waf1 in Human Malignant Mesothelioma

Raffaella Lazzarini1,2, Simona Moretti1,2, Sara Orecchia3, Pier-Giacomo Betta3, Antonio Procopio1,2 and Alfonso Catalano1,2

Authors' Affiliations: 1 Department of Molecular Pathology and Innovative Therapies, Marche University, Ancona, Italy; 2 Center of Cytology, Research Department, Italian National Research Centers on Aging, Ancona, Italy; and 3 Pathology Unit, Azienda Ospedaliera, Alessandria, Italy

Requests for reprints: Alfonso Catalano, Dipartimento di Patologia Molecolare, Politecnica delle Marche, Via Tronto 10/A, 60100, Ancona, Italy. Phone: 39-0712206245; Fax: 39-0712206240; E-mail: a.catalano{at}univpm.it.

Purpose: The p21 cyclin-dependent kinase inhibitor was frequently expressed in human malignant pleural mesothelioma (MPM) tissues as well as cell lines. Recent data indicate that p21 keeps tumor cells alive after DNA damage, favoring a survival advantage. In this study, we assessed the possibility of p21 suppression as a therapeutic target for MPM.

Experimental Design: We established two different MPM-derived (from H28 and H2052 cells) subclones using vector-based short hairpin RNA (shRNA). Then, chemosensitivity against low doses of antineoplastic DNA-damaging agents was investigated by colony formation assays, and furthermore, the type of cell response induced by these drugs was analyzed. To examine the effect of p21 shRNA on chemosensitivity in vivo, tumor formation assays in nude mice were done.

Results: In colony formation assay, the IC50 of doxorubicin was 33 ± 3.0 nmol/L in p21 shRNA-transfected cells with respect to 125 ± 10 nmol/L of control vector–transfected cells. This enhancement of growth inhibition was achieved by converting a senescence-like growth arrest to apoptosis in response to doxorubicin, etoposide, and CPT11. In the in vivo assays, CPT11 and loss-of-expression of p21 in combination led to considerable suppression of tumor growth associated with a substantially enhanced apoptotic response, whereas CPT11 alone was ineffective at inducing these responses.

Conclusions: These results indicated that p21 might play an important role in chemosensitivity to anticancer agents, and the suppression of its expression might be a potential therapeutic target for MPM.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.